In addition, the IL6ST targeted drug siltuximab is undergoing I/II trials for solid tumors, while the EPHB4-targeted drug tesevatinib is undergoing I/II trials for solid tumors and non small cell lung cancer. This evidence concerns the gene IL6ST and non-small cell lung carcinoma.